RxDoctor Payments DataLook up a doctor →

Neal Daniel, MD

Pulmonary Disease · Birmingham, ALNPI 1053525618

Payments from drug & device makers

$12,129in general payments, 2019–2025

Across 637 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$881
  • Mallinckrodt Hospital Products Inc.$837
  • Grifols USA, LLC$746
  • Regeneron Healthcare Solutions, Inc.$647
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$12,102100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,129 in reported general payments places this provider in the 75th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$118,193
Medicare patients
448
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter192$140,471
OfevNintedanib Esylate15$94,160
Breo ElliptaFluticasone/Vilanterol101$45,498
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$28,287
XareltoRivaroxaban16$9,194
Arnuity ElliptaFluticasone Furoate19$5,943
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,648
Wixela InhubFluticasone Propion/Salmeterol24$5,185
Albuterol Sulfate HfaAlbuterol Sulfate102$3,439
SymbicortBudesonide/Formoterol Fumarate11$2,997
Ventolin HfaAlbuterol Sulfate16$875
Fluticasone Propionate19$458
Montelukast Sodium38$327
Gabapentin12$126
Prednisone15$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$2,139$197,560324 claims
Boehringer IngelheimOfev$881$94,16015 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,320$31,28341 claims
Johnson & JohnsonXarelto$53$9,19416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →